NanoString Technologies Highlights Advances in Precision Oncology at the 60th Annual Meeting of the American Society of Hematology

SEATTLE, Nov. 29, 2018 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of more than 40 nCounter®-based research abstracts that will be presented at the 60th Annual Meeting of the American Society of Hematology being held December 1-4, in San Diego.

“We’re excited to see the extensive body of nCounter-based clinical and research studies that will be presented by our customers and collaborators at the ASH conference,” said Brad Gray, president and chief executive officer of NanoString. “These studies illustrate how the nCounter platform may be used to subtype lymphomas and optimize treatment regimens to contribute to better clinical outcomes for patients.”

The ASH Annual Meeting will include at least 14 oral presentations and more than 25 posters in various leukemia, lymphoma, and myeloma malignancies that demonstrate the utility of the nCounter platform across the heme-oncology spectrum.  These include 14 abstracts highlighting the potential clinical utility of NanoString’s nCounter Dx LymphMark™ Lymphoma Subtyping Test (LST) for directing treatment decisions, as well as multiple abstracts highlighting the relevance of the PanCancer IO360™ panel in leukemia and multiple new gene signatures on the nCounter platform. Several important abstracts are summarized below:

• High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Profiling: A Combined Analysis from Two Phase 2 Trials (Poster #2962)
  • A retrospective analysis of two studies showing that LymphMark identifies ABC-type DLBCL tumors that respond to R2CHOP
     
• Integration of NanoString Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies (Oral & Poster #676)
  • Profiling DLBCL with both LST and the PanCancer Immune Profiling (PCI) panel provide significant complementary information about prognosis for DLBCL patients
     
• The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL (Oral & Poster #921)
  • New gene signature from the British Columbia Cancer Agency that may be important in identifying a new subgroup of DLBCL for novel therapeutics such as EZH2 inhibitors
     
• Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (Oral & Poster #444)
  • Results from a collaboration between NanoString, Macrogenics, and Dr. Sergio Rutella from Nottingham Trent University showing that the IO360 panel may be able to identify patients with AML who respond to novel therapeutics
     
• Elevated LAG-3 Expression in the Tumor Microenvironment of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis (Poster #1576)
  • Profiling of DLBCL samples with LymphMark and PanCancer Immune panel shows significance of LAG3 expression in the ABC and unclassified subgroups may be important in directing immunotherapy combos with PD-1 and LAG3.
     
• Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) (Oral & Poster #764)
  • Results from a collaboration between NanoString, Macrogenics, and Dr. Sergio Rutella from Nottingham Trent University showing that the IO360 panel may be able to identify patients with AML who respond to novel therapeutics

The table below includes a selection of 2018 ASH abstracts that best illustrate the potential clinical utility of nCounter across multiple tumor types. To learn more about the capabilities of the nCounter platform, please visit NanoString at booth #2041 at ASH.

About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company’s nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company’s technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit Opens in new windowwww.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, IO 360, LymphMark, nCounter, and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Contact:

Doug Farrell
Vice President, Investor Relations & Corporate Communications
Opens in new windowdfarrell@nanostring.com
Phone: 206-602-1768

Source: NanoString Technologies, Inc.